Cortes discussed the evolution of chronic myeloid leukemia treatment and emerging strategies aimed at improving outcomes and quality of life. Dr. Jorge E. Cortes sat down with CURE to discuss the ...

Articles published in this focus collection were selected from recent issues of Leukemia. They highlight new developments in our understanding and management of persons with CML. CML was the first ...

An avid soccer player his whole life, Hans was used to the physical impact of the game. But at age 40, he slowly started to experience strange symptoms like exhaustion, weight loss and sporadic ...

A lower number of CD26+ LSCs at diagnosis correlates with optimal molecular response in CML patients at 3, 12, and 24 months.

A study suggests that lupus-like manifestations in patients with MDS/CMML frequently reflect clonal myeloid infiltration.

According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid blast phases of the ...

The advent of tyrosine kinase inhibitors (TKIs) has radically altered the outcome of patients with chronic myeloid leukemia (CML). Patients with chronic-phase disease can now expect a 10-year survival ...

Longitudinal, prospective cardiovascular and metabolic risk in treatment-naive patients with chronic myeloid leukemia in chronic phase (CML-CP) starting tyrosine kinase inhibitor (TKI) therapy in a ...

Chronic myeloid leukemia (CML) is a hematological tumor marked by the bcr-abl fusion gene formed by t (9;22) (q34;q11), which translated into the BCR-ABL protein. Tyrosine kinase inhibitors (TKIs) ...

It is important to distinguish de novo CML-BP from Ph-positive ALL before allogeneic hematopoietic cell transplantation. The effect of BCR::ABL1 mutation status on outcomes of hematopoietic cell ...

Lucknow: Chronic Myeloid Leukemia (CML) — which forms a major share of adult blood cancer cases in Uttar Pradesh — can now be effectively managed with.